Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is providing a $1 million grant to support development of the American Registry for Migraine Research. The American Migraine Foundation project involves publicly-available data and a biological repository.
The goal is to advance research efforts that lead to discoveries of treatments. It will also work toward training a network of investigative sites to collect more information.
American Migraine Foundation Chairman David Dodick says "we are enormously grateful for the vision and very generous support from Lilly to help the American Migraine Foundation build and sustain a patient registry and biorepository for migraine and other headache disorders. We believe the knowledge gained from this registry and the potential to identify clinical, laboratory, imaging and genetic biomarkers will usher in an era of precision medicine and generate new targets for generations of patients to come."
As part of the arrangement, Lilly will serve as a member of the Corporate Registry Roundtable, which involves proposing topics and study areas for the registry.
The organizations say around 12 percent of Americans suffer from migraines and more than $20 billion is spent on the condition each year in the United States. Migraine has no cure.